Lamisil

Terbinafine Hydrochloride, the active ingredient in Lamisil, is a allylamine antifungal presented as a topical formulation for skin use. It treats fungal infections of the skin, hair, and nails in adults and children as directed by a healthcare professional.

GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamisil (terbinafine) is used to treat fungal skin infections caused by dermatophytes.

- Tinea pedis (athlete's foot): reduces itching and clears infection on the feet. - Tinea corporis (ringworm): eliminates the expanding red ring lesions on the body. - Tinea cruris (jock itch): relieves irritation and eradicates the fungus in the groin area. - Tinea unguium (onychomycosis): improves nail appearance by inhibiting fungal growth within the nail plate.

Lamisil is generally well tolerated, but some users may experience local reactions.

Common Side Effects: - Itching at the application site - Redness or mild rash - Burning or stinging sensation - Dryness or peeling of the skin - Mild irritation or swelling - Scaling or flaking of the treated area

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Extensive skin rash or blistering (Stevens‑Johnson syndrome) - Swelling of face, lips, or tongue - Difficulty breathing or wheezing - Hepatotoxicity indicated by abnormal liver enzymes - Unusual bruising or bleeding

Before using Lamisil, consider the following safety measures.

- Pregnancy: consult a healthcare provider before application. - Breastfeeding: discuss potential risks with a doctor. - Apply only to intact, non‑broken skin. - Avoid extensive use on large body areas without medical advice. - Do not apply to mucous membranes, eyes, or genital mucosa. - Store at room temperature: keep in the original container, protect from moisture and light.

Terbinafine may interact with other medications; monitor for combined effects.

Major Interactions (Avoid): - Systemic azoles (e.g., itraconazole, fluconazole): may increase terbinafine plasma levels. - Strong CYP2D6 inhibitors (e.g., quinidine): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may mask local irritation. - Alcohol‑based skin products: could alter absorption. - Other dermatologic agents (e.g., salicylic acid, urea): may increase skin irritation.